F1I
AVBP icon

Fund 1 Investments’s ArriVent BioPharma AVBP Stock Holding History

Fund 1 Investments’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-499,990
Closed -$11.5M – 88
2026
Q1 		$11.5M Sell
499,990
-65,861
-12% -$1.49M 1.32% 22
2025
Q4 		$11.4M Sell
565,851
-54,000
-9% -$1.12M 1.39% 17
2025
Q3 		$11.4M Buy
619,851
+91,456
+17% +$1.8M 1.27% 22
2025
Q2 		$11.5M Buy
+528,395
New +$11M 0.93% 25

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fund 1 Investments's AVBP Position: Q2 2026 in Review

Fund 1 Investments sold out of ArriVent BioPharma (AVBP) in Q2 2026, closing a stake of 499,990 shares — an estimated $11.5M sold.

Fund 1 Investments first reported a position in AVBP in Q2 2025 and held it in 4 quarters. The position peaked at $11.5M in Q1 2026. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Fund 1 Investments reported no remaining ArriVent BioPharma position as of Q2 2026 after selling out during the quarter.
  • Fund 1 Investments sold 499,990 ArriVent BioPharma shares in Q2 2026, an estimated $11.5M.
  • Fund 1 Investments first reported a position in ArriVent BioPharma in Q2 2025 and held it in 4 quarters.
  • Fund 1 Investments's ArriVent BioPharma position peaked at $11.5M in Q1 2026.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Fund 1 Investments's 13F filing for Q2 2026, filed 14 Aug 2026.